{"entity":{"id":"nct05672524","kind":"trial","name":"A Study of Tucatinib and Trastuzumab in People With Rectal Cancer","aka":[],"tldr":"A phase 2 trial of trastuzumab and tucatinib in colorectal cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting.","summary":"A Study of Tucatinib and Trastuzumab in People With Rectal Cancer is a phase 2, interventional study registered as NCT05672524 by Memorial Sloan Kettering Cancer Center, with a registry enrolment figure of 37 participants, started 2022-12-30 and due to reach its primary completion in 2027-07-30. Interventions recorded: Trastuzumab; Tucatinib. Conditions listed: Adenocarcinoma of the Rectum; Locally Advanced Rectal Adenocarcinoma; Rectal Adenocarcinoma; HER2 Positive Rectal Adenocarcinoma; Rectal Cancer. Primary outcome: Clinical complete response of study participants. Colorectal eligibility wording from the registry: \"* Histologically confirmed rectal adenocarcinoma\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05672524","url":"https://clinicaltrials.gov/study/NCT05672524"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","her2-amplified-colorectal"],"sections":[],"technologies":["her2-tyrosine-kinase-inhibitors","kinase-inhibitors","monoclonal-antibody"],"targets":[],"drugs":["trastuzumab","tucatinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05672524","phase":"2","setting":"A Phase II Study of Induction Tucatinib and Trastuzumab With Total Neoadjuvant Therapy for Locally Advanced HER2-amplified Rectal Adenocarcinoma","sponsor":"Memorial Sloan Kettering Cancer Center","enrolled":37,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05672524/","neighbours":{"cancer":[{"id":"her2-amplified-colorectal","kind":"cancer","name":"HER2-amplified colorectal cancer","route":"/cancers/her2-amplified-colorectal/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"her2-tyrosine-kinase-inhibitors","kind":"technology","name":"HER2 tyrosine kinase inhibitors","route":"/technologies/her2-tyrosine-kinase-inhibitors/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"},{"id":"tucatinib","kind":"drug","name":"Tucatinib","route":"/drugs/tucatinib/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}